Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(19.13) by 81.7 percent. This is a 1490.91 percent decrease over losses of $(0.22) per share from the same period last year.